Active substances
Dextrose + Potassium chloride
- SFDA 1
- US FDA 19
- Health Canada 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| 0.3% POTASSIUM CHLORIDE in 5% DEXTROSE Injection USP | 5,0.3 %,% | Solution for infusion · Intravenous use | 1 Bag | SAR 18.00 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
Indications — CHI Daman Drug Formulary
FLUIDS AND VOLUME EXPANDERS-MAINTENANCE FLUIDS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER | 5GM/100ML;150MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 1 Feb 1979 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | 5GM/100ML;300MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 1 Feb 1979 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER | 5GM/100ML;224MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 1 Feb 1979 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER | 5GM/100ML;75MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 1 Feb 1979 |
| POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;149MG/100ML | injectable · injection | OTSUKA ICU MEDCL | Prescription | 29 May 1980 |
| POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;150MG/100ML | injectable · injection | B BRAUN | Prescription | 29 Sep 1989 |
| POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;300MG/100ML | injectable · injection | B BRAUN | Prescription | 29 Sep 1989 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% | 5GM/100ML;75MG/100ML | injectable · injection | FRESENIUS KABI USA | Prescription | 10 Sep 2020 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% | 5GM/100ML;150MG/100ML | injectable · injection | FRESENIUS KABI USA | Prescription | 10 Sep 2020 |
| POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;298MG/100ML | injectable · injection | OTSUKA ICU MEDCL | Discontinued | 29 May 1980 |
| POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;224MG/100ML | injectable · injection | OTSUKA ICU MEDCL | Discontinued | 29 May 1980 |
| POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;75MG/100ML | injectable · injection | B BRAUN | Discontinued | 9 Nov 1982 |
| POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;150MG/100ML | injectable · injection | B BRAUN | Discontinued | 9 Nov 1982 |
| POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;220MG/100ML | injectable · injection | B BRAUN | Discontinued | 9 Nov 1982 |
| POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;300MG/100ML | injectable · injection | B BRAUN | Discontinued | 9 Nov 1982 |
| POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;37MG/100ML | injectable · injection | B BRAUN | Discontinued | 29 Sep 1989 |
| POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;75MG/100ML | injectable · injection | B BRAUN | Discontinued | 29 Sep 1989 |
| POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;110MG/100ML | injectable · injection | B BRAUN | Discontinued | 29 Sep 1989 |
| POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER | 5GM/100ML;220MG/100ML | injectable · injection | B BRAUN | Discontinued | 29 Sep 1989 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| (20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 00438049 | 5 G / 100 ML; 150 MG / 100 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP | 00438030 | 5 G / 100 ML; 300 MG / 100 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.